KRAS and non-small cell lung carcinoma: Since KRAS G12C is the most frequent oncogenic driver mutation [27], Sotorasib and Adagrasib, which are currently approved in NSCLC UICC stage IV [8], combined with ICI could also potentially become future therapeutic options in stage III.